TRIUMPH trial programme: difference between revisions
Diff·revision 5 → 6·22:03, 11 Nov 2024
Difference between revision 5 and revision 6 of TRIUMPH trial programme. 3 lines changed; the page grew by 357 bytes.
| Revision 5 — 01:19, 22 Oct 2024 FiveOhThreeA (talk) add the confidence interval to the point estimate 2,480 bytes +524 | Revision 6 — 22:03, 11 Nov 2024 NeutralNikolai (talk) add the year of publication to each trial in the list 2,837 bytes +357 | ||
|---|---|---|---|
| 17 | A phase 2 trial is powered for dose selection rather than for effect estimation, so the confidence intervals around the larger figures are wide and the point estimates are the least reliable part of the result. This is a general property of phase 2 rather than a criticism of this trial.{{r|ich_e9}} | 17 | A phase 2 trial is powered for dose selection rather than for effect estimation, so the confidence intervals around the larger figures are wide and the point estimates are the least reliable part of the result. This is a general property of phase 2 rather than a criticism of this trial.{{r|ich_e9}} |
| 18 | 18 | ||
| + | 19 | Two dose-related safety observations were reported: a heart-rate increase larger than that typical of GLP-1 monotherapy, and transient rises in fasting glucose at low doses in participants with diabetes. Both are attributable to the glucagon component and are the predicted consequences of the design.{{r|coskun2022}} | |
| + | 20 | ||
| 19 | == References == | 21 | == References == |
| 20 | {{reflist}} | 22 | {{reflist}} |
| ⋮ | ⋮ | ||
| 26 | [[Category:Clinical trial programmes]] | 28 | [[Category:Clinical trial programmes]] |
| 27 | [[Category:Obesity trials]] | 29 | [[Category:Obesity trials]] |
| + | 30 | [[Category:Articles needing updates]] | |
| 28 | 31 |